Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, September 02, 2017 ) Market Research Hub (MRH) added a new research report to its vast database titled “Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) Pipeline Review, H2 2017” targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics development with respective active and dormant or discontinued projects.
Request Free Sample Report @ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1313669
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Peroxisome proliferator-activated receptor delta is a nuclear receptor that in humans is encoded by the PPARD gene. PPAR-delta is a nuclear hormone receptor that governs a variety of biological processes and involved in the development of several chronic diseases, including diabetes, obesity, atherosclerosis, and cancer. The expression of this gene is found to be elevated in colorectal cancer cells. The elevated expression can be repressed by adenomatosis polyposis coli (APC), a tumor suppressor protein involved in the APC/beta-catenin signaling pathway.
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 4, 3 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Gastrointestinal, Musculoskeletal Disorders, Central Nervous System, Immunology, Oncology, Genetic Disorders, Genito Urinary System And Sex Hormones, Ophthalmology and Respiratory which include indications Non-Alcoholic Steatohepatitis (NASH), Alzheimer's Disease, Dyslipidemia, Non Alcoholic Fatty Liver Disease (NAFLD), Primary Biliary Cirrhosis, Type 2 Diabetes, Bone Disorders, Bone Fracture, Cachexia, Colitis, Duchenne Muscular Dystrophy, Familial Chylomicronemia (Type I Hyperlipoproteinemia), Fibrosis, Homozygous Familial Hypercholesterolemia (HoFH), Hypertriglyceridemia, Idiopathic Pulmonary Fibrosis, Inflammation, Inherited Metabolic Disorders, Kidney Disease, Liver Diseases, Metabolic Syndrome, Mitochondrial Diseases, Mixed Dyslipidemia, Multiple Sclerosis, Obesity, Osteoarthritis, Osteoporosis, Parkinson's Disease, Systemic Lupus Erythematosus and Systemic Sclerosis (Scleroderma).
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Scope: - The report provides a snapshot of the global therapeutic landscape for Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - The report reviews Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics and enlists all their major and minor projects - The report assesses Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics
Browse Full Report with TOC @ http://www.marketresearchhub.com/report/peroxisome-proliferator-activated-receptor-delta-nuci-or-nuclear-hormone-receptor-1-or-nuclear-receptor-subfamily-1-group-c-member-2-or-peroxisome-proliferator-activated-receptor-beta-or-nr1c2-or-ppard-pipeline-review-h2-2017-report.html
Reasons to buy: - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Content:
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Overview Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Companies Involved in Therapeutics Development Chipscreen Biosciences Ltd Connexios Life Sciences Pvt Ltd CymaBay Therapeutics Inc Genfit SA Inventiva Mitobridge Inc Nippon Chemiphar Co Ltd Senju Pharmaceutical Co Ltd T3D Therapeutics Inc vTv Therapeutics Inc ….continue
Make an Enquiry @ http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1313669
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of pharmaceutical market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients and customers.
Contact Us 90 State Street, Albany, NY 12207, United States Toll Free: 800-998-4852 (US-Canada) Email: press@marketresearchhub.com Website: http://www.marketresearchhub.com/ Read Industry News at - https://www.industrynewsanalysis.com/
Market Research Hub
Sudip S
+1-518-621-2074
sales@marketresearchhub.com
Source: EmailWire.Com
Source: EmailWire.com
|
|
|
|